首页> 美国卫生研究院文献>Journal of Diabetes Science and Technology >Pioglitazone Improves Metabolic Markers in Patients with Type 2 Diabetes Independently from Physical Activities: Results from the IRIS III Study

【2h】

Pioglitazone Improves Metabolic Markers in Patients with Type 2 Diabetes Independently from Physical Activities: Results from the IRIS III Study

机译：吡格列酮可独立于体育活动改善2型糖尿病患者的代谢指标：IRIS III研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AimPioglitazone is an established peroxisome proliferator-activated receptor γ agonist for the treatment of insulin resistance in patients with type 2 diabetes mellitus. This analysis of the observational IRIS III study was performed to evaluate the effects of pioglitazone treatment in relation to the degree of physical exercise activities in a large patient population under daily life conditions.

机译：AimPioglitazone是已建立的过氧化物酶体增殖物激活受体γ激动剂，用于治疗2型糖尿病患者的胰岛素抵抗。这项对IRIS III观察性研究的分析旨在评估吡格列酮治疗与日常生活条件下大量患者体育锻炼活动程度的关系。

著录项

期刊名称 Journal of Diabetes Science and Technology
作者
Thomas Schöndorf; Andreas Pfützner; Georg Lübben; Efstrathios Karagiannis; Werner Roth; Thomas Forst;
展开▼
作者单位

展开▼
年(卷),期 2008(2),2
年度 2008
页码 244–249
总页数 6
原文格式 PDF
正文语种
中图分类基础医学;
关键词
diabetes exercise glitazones metabolism;

机译：糖尿病;运动;格列酮;新陈代谢;

相似文献

外文文献
中文文献
专利

1. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions. [J] . Schondorf T, Karagiannis E, Posseldt RE, Diabetes technology & therapeutics . 2009,第6期

机译：吡格列酮和二甲双胍的固定结合药物Competact改善了仅通过二甲双胍无法控制血糖的2型糖尿病患者的代谢指标-这是在日常例行条件下进行的上市后监测试验得出的结果。
2. Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions. [J] . Schondorf T, Karagiannis E, Posseldt RE, Diabetes technology & therapeutics . 2009,第6期

机译：吡格列酮和二甲双胍的固定结合药物Competact改善了仅通过二甲双胍无法控制血糖的2型糖尿病患者的代谢指标-这是在日常例行条件下进行的上市后监测试验得出的结果。
3. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. [J] . Aronoff S, Rosenblatt S, Braithwaite S, Diabetes care . 2000,第11期

机译：盐酸吡格列酮单药治疗可改善2型糖尿病患者的血糖控制：一项为期6个月的随机安慰剂对照剂量反应研究。吡格列酮001研究组。
4. A Recommendation System of Nutrition and Physical Activity for Patients with Type 2 Diabetes Mellitus [C] . Joao Godinho, Sara Batista, Diogo Martinho, International Conference on Intelligent Data Engineering and Automated Learning . 2020

机译：2型糖尿病患者的营养和身体活动建议制度
5. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
6. Fixed-dose combination of alogliptin/pioglitazone improves glycemic control in Japanese patients with type 2 diabetes mellitus independent of body mass index [O] . Chie Aoki, Kunihiro Suzuki, Hisamoto Kuroda, 2017

机译：与体重指数无关的阿格列汀/吡格列酮固定剂量组合可改善日本2型糖尿病患者的血糖控制
7. Pioglitazone Improves Metabolic Markers in Patients with Type 2 Diabetes Independently from Physical Activities: Results from the IRIS III Study [O] . Schöndorf, Thomas, Pfützner, Andreas, Lübben, Georg, 2008

机译：吡格列酮可独立于体育活动改善2型糖尿病患者的代谢指标：IRIS III研究的结果

Pioglitazone Improves Metabolic Markers in Patients with Type 2 Diabetes Independently from Physical Activities: Results from the IRIS III Study

摘要

著录项

相似文献

相关主题

期刊订阅